Company news: Gilead, Pfizer and Wolters Kluwer

Share this article:

Two potential blockbusters in the pharma pipeline took another step toward reaching market. US regulatory authorities assigned August 2012 PDUFA dates for Gilead Sciences' Quad pill and for Pfizer's tofacitinib. Quad is a single-tablet HIV regimen containing four agents, while tofacitinib is set to become the first oral rheumatoid arthritis drug to enter the injectable RA space. NDAs for both drugs had been submitted earlier this year.

Wolters Kluwer said it completed the sale of its pharma-related marketing & publishing services business to Springer Science+Business Media. The sale, announced in November, is part of Wolters Kluwer's strategy to focus on core health markets through its Wolters Kluwer Health & Pharma Solutions division.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.